The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer’s disease

By Thompson Sarah   Lanctôt Krista L   Herrmann Nathan  

Expert Opinion on Drug Safety, Vol. 3, Iss. 5, 2004-09 ,pp. : 425-440

Informa Healthcare

Access to resources Recommend Favorite

Discontinuation of Cholinesterase Inhibitor Treatment and Determinants thereof in the Netherlands: A Retrospective Cohort Study

By Kröger Edeltraut   >  

Drugs & Aging, Vol. 27, Iss. 8, 2010-08 ,pp. : 663-675

Adis International

Access to resources Recommend Favorite

Patient Satisfaction with Switching to Esomeprazole from Existing Proton Pump Inhibitor Therapy for Gastro-Oesophageal Reflux Disease: An Observational, Multicentre Study

By Hoogendoorn Robert J.  

Clinical Drug Investigation, Vol. 29, Iss. 12, 2009-12 ,pp. : 803-810

Adis International

Access to resources Recommend Favorite

Frequency and Clinical Relevance of Drug Interactions with Lovastatin and Simvastatin: An Observational Database Study

By Tirkkonen Tuire   Ryynänen Anna  

Drug Safety, Vol. 31, Iss. 3, 2008-01 ,pp. : 231-240

Adis International

Access to resources Recommend Favorite

Is Long-Term Treatment of Alzheimer's Disease with Cholinesterase Inhibitor Therapy Justified?

By Seltzer Ben  

Drugs & Aging, Vol. 24, Iss. 11, 2007-01 ,pp. : 881-890

Adis International

Access to resources Recommend Favorite